MHRA Approves New Medical Cannabis Flower Product for UK Market

The Medicines and Healthcare products Regulatory Agency has approved a new medical cannabis flower product for the UK market, bringing additional options to clinicians and patients seeking botanical cannabis-based medicines. The approval marks another step in the ongoing expansion of the UK's medical cannabis formulary.

About the Approved Product

The newly approved product is a dried cannabis flower preparation standardised for both THC and CBD content, cultivated under Good Agricultural and Collection Practice standards. It is intended for vaporisation using an approved medical vaporiser device and is indicated for use in adult patients where other treatment options have proved inadequate.

• Standardised cannabinoid profile with defined THC and CBD concentrations
• Cultivated to pharmaceutical-grade standards
• Approved for administration via medical vaporiser only
• Indicated for adults with treatment-resistant conditions

Regulatory Context

The MHRA approval process for cannabis-based medicines involves a thorough review of manufacturing quality, safety data, and clinical evidence. Products that receive full approval carry a significantly higher level of regulatory assurance than those prescribed under the Specials licensing framework, which has been the basis for most UK medical cannabis prescribing to date. Expanding the number of fully approved products is expected to increase prescriber confidence and may ultimately support a shift toward broader NHS prescribing.

The approved product will be available through licensed medical cannabis clinics and dispensing pharmacies. Patients can explore currently available flower products in our strain directory or find a clinic through our clinic finder. Our prescription guide explains how to access prescribed products through the formal clinical pathway.